drugset / Trial / NCT04077892

Compare the Effect of INS Alone and Added LTRA in Treatment of SAR

NCT04077892

Phase 0 Completed 46 enrolled Beijing Tongren Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

It is not proven unequivocally whether a combination of an intranasal corticosteroids (INS) and a cysteinyl leukotriene receptor antagonist has greater efficacy than INS in the treatment of severe allergic rhinitis (AR) . We performed a randomized, open-label study in 46 seasonal AR subjects receiving budesonide (BD, 256ug) plus montelukast (MNT, 10 mg) or BD alone (256ug) for 2 weeks. Visual analog scale (VAS) scores, nasal cavity volume (NCV), nasal airway resistance (NAR) and fractional exhaled nitric oxide (FeNO) were assessed before and at end of treatments as the primary treatment outcomes. Similarly, histamine, eosinophil cationic protein (ECP) and cysteinyl-leukotrienes (Cyslts) in nasal secretion and Th1/Th2 cells in nasal mucosa were evaluated as the secondary treatment outcomes.

Timeline

Start
2016-06-01
Primary completion
2016-09-30
Completion
2016-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 256 ug Intranasal
Subject Montelukast Other / unclassified 10 mg Oral

Indications